All Sectors Except Digestive Remedies Experienced Growth in the German OTC Market.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c40764) has announced the addition of Digestive Remedies in Germany to their offering.

Our Digestive Remedies in Germany report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2000-2005), allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2010 illustrate how the market is set to change.

Product coverage: Indigestion and heartburn remedies, laxatives, diarrheal remedies, motion sickness remedies, child-specific digestive remedies

Data coverage: market sizes (historic and forecasts), company shares, brand shares

Why buy this report?

--Get a detailed picture of the digestive remedies industry

--Pinpoint growth sectors and trends and identify factors driving change

--Understand the competitive environment, the market's major players and leading brands

--Use five-year forecasts to assess how the market is predicted to develop

With a network of over 600 analysts worldwide, we have a unique capability to develop reliable information resources to help drive informed strategic planning.

Topics Covered
1. EXECUTIVE SUMMARY

2. OPERATING ENVIRONMENT
- 2.1 OTC Registration and Classification
- 2.2 Vitamins and Dietary Supplements Registration and Classification
- 2.3 Advertising
- 2.4 Packaging and Labelling
- 2.5 Distribution
- 2.6 Delisting or De-reimbursement
- 2.7 Traditional Remedies
- 2.8 Homoeopathy
- 2.9 Generics
- 2.10 Consumer Expenditure on Health Goods and Medical Services

- 2.11 Life Expectancy

3. OTC HEALTHCARE SALES
- 3.1 Market Performance
- 3.2 Switches
- 3.3 Key Trends and Developments
- 3.4 Competitive Environment
- 3.5 Leading Company Profile - Aventis Pharma Deutschland GmbH
      (Nattermann & Cie GmbH)
- 3.6 Leading Company Profile - Bayer Group (Bayer Vital GmbH)
- 3.7 Leading Company Profile - Beiersdorf AG
- 3.8 Leading Company Profile - Boehringer Ingelheim Pharma GmbH &
      Co KG
- 3.9 Leading Company Profile - GlaxoSmithKline GmbH & Co KG
- 3.10 Leading Company Profile - Johnson & Johnson GmbH
- 3.11 Leading Company Profile - Merck KGaA
- 3.12 Leading Company Profile - Novartis Consumer Health GmbH
- 3.13 Leading Company Profile - Procter & Gamble GmbH
- 3.14 Leading Company Profile - Ratiopharm GmbH & Co
- 3.15 Leading Company Profile - Stada Arzneimittel AG
- 3.16 Leading Company Profile - Viatris GmbH & Co KG (formerly known
       as Asta Medica AG)
- 3.17 Emerging and Niche Companies
- 3.18 Retail Distribution
- 3.19 Retailer Activity and Private Label Trends
- 3.20 Forecast Market Performance

4. DIGESTIVE REMEDIES SALES
- 4.1 Sector Performance
- 4.2 New Product Developments
- 4.3 Digestive Remedies by Herbal/Standard Split
- 4.4 Other Indigestion and Heartburn Remedies Performance

5. DEFINITIONS

Summary

A good year in 2005

The German OTC health market registered healthy growth in 2005, with value sales rising at a rate significantly above the CAGR for the review period. This positive development was underpinned by increased health consciousness, the effects of the ubiquitous wellness trend and - particularly - the ongoing effects of the health reforms, which came into effect in June 2004.

All sectors experienced growth with the exception of digestive remedies, with the strongest sales growth registered by preventive healthcare products and OTC products related to stress-relief, such as vitamins and dietary supplements, NRT smoking cessation aids, eye care and calming and sleeping products.

Pharmacies remain the most important distribution channel for OTC healthcare products, despite timid moves towards the liberalisation of distribution. Generics and private label products are important in certain areas and have benefited from ongoing difficult economic conditions, characterised by low consumer confidence and consequent sensitivity to prices.

Companies Mentioned Include:

- Bayer Vital GmbH - Novartis Consumer Health GmbH - Boehringer Ingelheim Pharma GmbH & Co KG - Beiersdorf AG - Ratiopharm GmbH & Co - Abtei Pharma Vertriebs-GmbH - Procter & Gamble GmbH - STADA Arzneimittel AG - Whitehall Much GmbH - MCM Klosterfrau Vertriebgesellschaft mbH - Mann Chem-Pharm Fabrik GmbH, Dr Gerhard - Madaus AG - Bayer Group (Bayer Vital GmbH) - Bad Heilbrunner Naturheilmittel GmbH & Co - Godecke AG - Solvay Arzneimittel GmbH - Merck KGaA - Woelm Pharma GmbH & Co - Impuls-Vermarktung GmbH & Co KG - Spitzner Arzneimittel GmbH - Boots Healthcare Deutschland GmbH - Roche Consumer Health Deutschland GmbH - McNeil GmbH & Co - Ricola AG - Viatris GmbH & Co KG (formerly known as Asta Medica AG) - Hexal AG - Pfizer Consumer Healthcare GmbH - Engelhard Arzneimittel GmbH and Co KG - Aventis Pharma Deutschland GmbH (Nattermann & Cie GmbH) - Nattermann & Cie GmbH - Weleda AG - Lichtwer Pharma AG - Pohl-Boskamp GmbH und Co - Johnson & Johnson GmbH - Dr Rentschler Arzneimittel GmbH & Co - GlaxoSmithKline GmbH & Co KG - Wolff GmbH & Co Arzneimittel, Dr August

For more information visit http://www.researchandmarkets.com/reports/c40764